Last reviewed · How we verify
Revolade®
Revolade (eltrombopag) is a thrombopoietin receptor agonist that stimulates platelet production by binding to and activating the TPO receptor on bone marrow progenitor cells.
Revolade (eltrombopag) is a thrombopoietin receptor agonist that stimulates platelet production by binding to and activating the TPO receptor on bone marrow progenitor cells. Used for Chronic immune thrombocytopenia (ITP), Thrombocytopenia in patients with chronic hepatitis C, Severe aplastic anemia.
At a glance
| Generic name | Revolade® |
|---|---|
| Also known as | Eltrombopag |
| Sponsor | Centro de Atencion e Investigacion Medica |
| Drug class | Thrombopoietin receptor agonist |
| Target | TPO receptor (TPOR/MPL) |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
Eltrombopag is a small-molecule, oral TPO receptor agonist that mimics the action of thrombopoietin, a natural hormone that regulates platelet production. By activating TPO receptors on megakaryocyte progenitor cells in the bone marrow, it increases platelet production and raises platelet counts in patients with thrombocytopenia. This mechanism helps restore adequate platelet levels in conditions where platelet production is impaired or platelet destruction is excessive.
Approved indications
- Chronic immune thrombocytopenia (ITP)
- Thrombocytopenia in patients with chronic hepatitis C
- Severe aplastic anemia
Common side effects
- Headache
- Diarrhea
- Nausea
- Fatigue
- Thromboembolic events
Key clinical trials
- High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly (PHASE2)
- Bioequivalence Study of Revolade® Eltrombopag 50 mg (PHASE4)
- A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia (PHASE2)
- Immunomodulation With Eltrombopag in ITP (PHASE2)
- REscuing Bone Marrow Function in Patients with AplaStic AnaEmia and Bone Marrow FaiLure Post AllogEneiC Transplantation 2 (PHASE1, PHASE2)
- Study of Efficacy, Safety and Immunogenicity of GP40141 (GEROPHARM, Russia) in Patients With Immune Thrombocytopenia (PHASE3)
- Eltrombopag for Treatment of Fanconi Anemia (PHASE2)
- Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |